<DOC>
	<DOCNO>NCT00468143</DOCNO>
	<brief_summary>The purpose pilot study compare Adderall ® Adderall XR ® term effectiveness side effect treatment ADHD adult .</brief_summary>
	<brief_title>A Within-Subject Cross-Over Comparison Between Immediate Release Extended Release Adderall</brief_title>
	<detailed_description>This randomize , cross-over study adult ADHD receive three week treatment Adderall ( IR ) ( 15 , 30 , 45 mg TID ) three week treatment Adderall XR ( XR ) ( 15 , 30 , 45 mg QD ) evaluation dose adherence treatment efficacy . The order two condition ( TID-QD QD-TID ) counterbalance across subject , washout period treatment period . Participants require come site 9 visit approximately 8-week period . The study consist follow four phase : - Phase 1 - Screening Visit ( Visit 1 ) - Treatment `` A '' Baseline Visit ( Visit 2 ) - Phase 2 Treatment Period `` A '' - participant take either Adderall Adderall XR 3 week ( Visits 3-5 ) - Phase 3 - 7-Day Washout Period - participant Treatment `` A '' medication - Treatment `` B '' Baseline visit ( Visit 6 ) - Phase 4 Treatment Period `` B '' - participant take either Adderall Adderall XR 3 week ( Visits 7-9 ) Eligible participant randomize 1:1 ratio one two schedule treatment , Adderall IR follow Adderall XR , Adderall XR follow Adderall IR . Within schedule , treatment consist 3-week dose optimization titration evaluation period washout week prior switch second respective treatment . The maximum total daily dose 45mg , 15mg TID IR 45mg QD XR . Throughout medication treatment period , participant visit clinic weekly evaluation efficacy , tolerance , adherence . Medical evaluation also conduct treatment visit , include assessment weight , blood pressure , pulse . Efficacy adherence data collect separate research staff , rater evaluate efficacy blind adherence result . The clinician evaluating efficacy also blind participant ' treatment assignment .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>1 . At time consent , age 1855 , inclusive . 2 . Meet DSMIV criterion ADHD assess Adult ADHD Clinician Diagnostic Scale ( ACDS ) v1.2 . 3 . Female participant childbearing potential must test negative pregnancy time enrollment base urine pregnancy test agree use reliable method birth control study . Females childbearing potential defined woman surgically sterilize menarche 2 year postmenopause . 4 . Must satisfactory medical assessment clinically significant abnormality determine medical history , physical exam , ECG , clinical laboratory test . 5 . Must able swallow capsule . 6 . Must able begin daily dose study medication morning . 7 . Must previous amphetamine methylphenidate treatment 1 week prior baseline ( visit 2 ) . Must past nonstimulant ADHD medication ( i.e. , atomoxetine ) 3 week prior baseline ( visit 2 ) . 8 . In opinion investigator , subject must understand able , willing likely fully comply study procedure restriction . 9 . Must give sign date informed consent accordance Good Clinical Practice ( GCP ) Guidelines . 1 . Lifetime present history bipolar disorder , schizophrenia schizoaffective disorder . 2 . Uncontrolled comorbid major depressive disorder , anxiety disorder dysthymia . Participants control depressive anxiety disorder may participate medication stabilize minimum four week , opinion Principal Investigator , interfere adherence , safety , efficacy assessment . 3 . Anyone meet current DSMIVTR criterion alcohol nonalcohol substance abuse dependence disorder ( exclude nicotine ) . 4 . Have organic brain disease ( dementia ) traumatic brain injury residuum . Have history seizure disorder ( febrile seizure ) participant take ( currently take ) anticonvulsant seizure control . 5 . Females currently pregnant breast feeding , woman childbearing potential currently use adequate form birth control . 6 . Participants clinically significant ECG laboratory abnormality screen deem exclusionary opinion Principal Investigator . 7 . Participants work night shift another schedule would preclude begin daily dose study medication morning . 8 . Participants positive urine drug result Screening . 9 . Participants concurrent chronic acute illness unstable medical condition could , opinion study physician , confound result safety assessment , increase risk subject lead difficulty comply protocol . Subjects history mental retardation severe learn disability exclude . 10 . Participants history structural cardiac abnormality well condition may affect cardiac performance . 11 . Participants document history allergy , intolerance , nonresponsivity methylphenidate amphetamine . This include history two fail stimulant treatment trial , deem Principal Investigator . 12 . Participants investigator 's opinion meet exclusionary criterion specify FDA label either Adderall Adderall XR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>